| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1/2 data readout example | Phase 1/2 | — | Subscribe to access the data. | Cell Therapies | Oncology | ||
Phase 1/2 data readout example | Phase 1/2 | — | Subscribe to access the data. | Cell Therapies | Oncology | ||
Phase 1/2 data readout example | Phase 1/2 | — | Subscribe to access the data. | Cell Therapies | Oncology |
Recent Updates
Recently added Catalysts
Lyell Immunopharma, Inc.$15.01
-0.2 (-1.31%)
D 36Pipeline Score Overvalued Biotech · Clinical
Market Cap
407.41 M
EPS
-12.74
P/E Ratio
-
Value Trade
5.31 M
SEC Financials
Q1 2026Dilution Risk
25%Revenue
2.00 K
R&D Expenses
36.60 M
Operating CF
-38.51 M
Total Assets
350.63 M
Total Liabilities
76.96 M
Equity
273.67 M
D/E Ratio
12,345
-5.93 %
Week
-28.44 %
1 Month
-17.84 %
3 Month
-1.74 %
6 Month
-95.34 %
5 Year
-95.34 %
All Time
Cash Data
Cash Position
254.02 M
Monthly Burn
12.84 M
Runway
17.9 mo
Burn Trend
StableSEC Filing
May 6, 2026
Overview
Volume
116.57 K
52 Week Range
7.65 - 45
% held by Insiders
70.8 %
% held by Institutions
18.91 %
Enterprise Value
202.24 M
Total Shares
21.22 M
Short %
18.53 %
Float Shares
6.60 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Lyell Immunopharma, Inc.
276Total events
15Upcoming
49Tier-1 (high impact)
2021 – 2027Coverage
Upcoming catalysts 15
Event history 261
Q3 2026
◆Additional Dataronde-celClinical Data
Additional data from PiNACLE pivotal trial expected in second half of 2026
large B-cell lymphoma (LBCL) third- or later-linesource ↗
Q3 2026
◆Additional DataLYL273Clinical Data
Second data update including clinical outcomes from LYL273 Phase 1 trial expected in second half of 2026
metastatic colorectal cancer (mCRC)source ↗
Jun 30, 2026
◆Oral PresentationPresentation
Lyell management to participate in fireside chat at H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
Jun 12, 2026
◆Poster Presentationronde-celPresentation
Poster presentation of updated safety analysis and translational data for ronde-cel at EHA 2026
relapsed or refractory large B-cell lymphomasource ↗
Jun 12, 2026
◆Poster Presentationrondecabtagene autoleucelPresentation
Safety data and translational insights for ronde-cel presented at EHA 2026
relapsed or refractory large B-cell lymphomasource ↗
Jun 12, 2026
▲Safety Data Updaterondecabtagene autoleucelClinical Data
Updated safety data: no Grade ≥3 CRS, low Grade ≥3 ICANS in 108 patients
relapsed or refractory large B-cell lymphomasource ↗
Jun 12, 2026
▲Biomarker Datarondecabtagene autoleucelClinical Data
Translational data: Tcmp cells associated with durable responses, CD62L+ enrichment and dual-targeting
relapsed or refractory large B-cell lymphomasource ↗
Jun 8, 2026
◆Oral PresentationPresentation
Lyell management to participate in Goldman Sachs 47th Annual Global Healthcare Conference 2026
Jun 8, 2026
▲Safety Data UpdateLYL273Clinical Data
Updated safety data: GI prophylaxis reduced Grade ≥2 diarrhea/colitis from 55% to 10%
relapsed or refractory metastatic colorectal cancersource ↗
Jun 8, 2026
●Protocol AmendmentLYL273Trial
Phase 1 trial amended to Phase 1/2 design enabling seamless expansion into potential pivotal single-arm Phase 2
relapsed or refractory metastatic colorectal cancersource ↗
May 20, 2026
May 19, 2026
◆Oral PresentationPresentation
H.C. Wainwright 4th Annual BioConnect Investor Conference fireside chat
Drug Pipeline Intelligence
D36
Pipeline Score $72M
Pipeline ValueOvervalued
Valuation Signal2
Drugs Scored0.2x
rNPV / MCap Top 49%
Micro Cap (rank 466 of 911)
Percentile RankLyell Immunopharma, Inc. faces pipeline headwinds (36/100), with $207M risk-adjusted pipeline value, led by rondecabtagene autoleucel in Large B-cell Lymphoma (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| rondecabtagene autoleucel Monoclonal antibody | Large B-cell Lymphoma | Phase 3 | NCT07188558 | 48% | $190M | RECRUITING | 400 | FAST | C (52) | Jan 1, 2032 | VERY_HIGH_RISK | LOW Jun 8, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
rondecabtagene autoleucel | relapsed or refractory large B-cell lymphoma | Phase 1/2 | 2026-06-12 | 97% manufacturing success rate; no Grade ≥ 3 CRS; Grade 1 CRS events were reported in 56% (36/64); Grade 2 in 13% (8/64); Grade ≥ 3 events of ICANS occurred in 8% (5/64); 16% (7/44) of patients who did not receive prophylaxis Read More | Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congress Read More | |
rondecabtagene autoleucel | relapsed or refractory large B-cell lymphoma | Phase 1/2 | 2026-06-12 | 97% manufacturing success rate; no Grade ≥ 3 CRS; Grade 1 CRS events were reported in 56% (36/64); Grade 2 in 13% (8/64); Grade ≥ 3 events of ICANS occurred in 8% (5/64); 16% (7/44) of patients who did not receive prophylaxis Read More | Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congress Read More | |
rondecabtagene autoleucel | relapsed or refractory large B-cell lymphoma | Phase 1/2 | 2026-06-12 | 97% manufacturing success rate; no Grade ≥ 3 CRS; Grade 1 CRS events were reported in 56% (36/64); Grade 2 in 13% (8/64); Grade ≥ 3 events of ICANS occurred in 8% (5/64); 16% (7/44) of patients who did not receive prophylaxis Read More | Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congress Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in LYEL
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
LYEL Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-10-16 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-10-16 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-10-16 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
LYELLyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
Lyell Immunopharma announced its participation in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference, scheduled for June 30, 2026. Senior management will engage in a fireside chat, discussing the company's advancements in CAR T-cell therapies for cancer. The event will be accessible via a live webcast on Lyell's website.
Read more →LYELLyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congress
Lyell Immunopharma presented updated safety data for rondecabtagene autoleucel (ronde-cel) at the EHA 2026 Congress. The data showed a 97% manufacturing success rate and no Grade 3 or higher cytokine release syndrome (CRS), supporting outpatient treatment. The translational insights suggest enhanced memory potential of T-cells and dual-targeting efficacy. Further pivotal trial data is expected in the coming years.
Read more →LYELLyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion
Lyell Immunopharma has updated the safety profile of its CAR T-cell therapy, LYL273, in a Phase 1 trial for relapsed or refractory metastatic colorectal cancer. The trial has been amended to allow for a potential Phase 2 expansion. Notably, gastrointestinal prophylaxis significantly reduced severe side effects. The company anticipates more clinical data and an FDA meeting by late 2026.
Read more →LYELLyell Immunopharma to Present Phase 1/2 Safety and Translational Data for Ronde-Cel in Large B-Cell Lymphoma at the European Hematology Association 2026 Congress
Lyell Immunopharma announced it will present data from its Phase 1/2 trial of ronde-cel for relapsed or refractory large B-cell lymphoma at the EHA 2026 Congress in Stockholm. The two poster presentations will cover an updated safety analysis showing low-grade CRS and ICANS, as well as insights into durable responses associated with the infusion product's cytotoxic T cell memory potential. The ongoing clinical investigation is expected to pave the way for potential regulatory submissions in the coming years.
Read more →LYELLyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026
Lyell Immunopharma, a late-stage clinical company focused on CAR T-cell therapies, will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026. The event will feature a fireside chat where senior management will discuss the company’s innovations in cancer treatment. Lyell aims to improve the efficacy of CAR T-cells through advanced technologies, with a production capacity of over 1,200 doses annually. However, the company acknowledges risks and uncertainties associated with its forward-looking statements.
Read more →LYELLyell Immunopharma Announces Participation in May Investor Conferences
Lyell Immunopharma announced its participation in two upcoming investor conferences in May 2026. The events include the H.C. Wainwright 4th Annual BioConnect Investor Conference and the Stifel Virtual Targeted Oncology Forum. The company aims to showcase its advancements in CAR T-cell therapies for cancer patients. Live webcasts of the events will be available on their website.
Read more →LYELLyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026
Lyell Immunopharma reported its first quarter 2026 results, highlighting progress in its clinical trials, particularly for ronde-cel, a CAR T-cell therapy for large B-cell lymphoma. The company has commenced patient dosing in pivotal trials and secured $261 million in cash, providing a financial runway into 2027. Despite a reduced net loss compared to the previous year, challenges remain in clinical development and manufacturing.
Read more →LYELLyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare Conference
Lyell Immunopharma announced its participation in the 25th Annual Needham Virtual Healthcare Conference, scheduled for April 14, 2026. Senior management will present insights on their innovative CAR T-cell therapies aimed at treating cancer. The company emphasizes its advanced manufacturing capabilities and the potential of its product pipeline. A live webcast of the presentation will be available on their website.
Read more →LYEL▼ -14.2%on this news
Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results
Lyell Immunopharma reported its Q4 and full-year 2025 financial results, highlighting advancements in its CAR T-cell therapy pipeline. The company has initiated a Phase 3 trial for ronde-cel in large B-cell lymphoma and has dosed patients with LYL273 for colorectal cancer. Despite a net loss of $140.7 million in Q4, Lyell remains optimistic about upcoming clinical milestones and the potential of its product candidates.
Read more →LYEL▲ +13.5%on this news
Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer
Lyell Immunopharma has announced the closing of an additional $50 million tranche from its $100 million equity private placement, following a clinical milestone in its pivotal trial for rondecabtagene autoleucel. The company has also appointed Smital Shah as Chief Financial and Business Officer, expected to guide its financial strategy. This funding is anticipated to support operations into the second quarter of 2027.
Read more →LYEL▲ +6.1%on this news
Lyell Immunopharma Announces Participation in March Investor Conferences
Lyell Immunopharma announced its participation in upcoming investor conferences, showcasing its advancements in CAR T-cell therapies for cancer treatment. The company's management will present at these events, which will be accessible via live webcasts. Lyell's manufacturing capabilities are highlighted, emphasizing its potential for commercial launch.
Read more →LYELLyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-To-Head CAR T-Cell Clinical Trial in Aggressive Large B-Cell Lymphoma
Lyell Immunopharma has initiated patient dosing in its Phase 3 PiNACLE – H2H trial, comparing its CAR T-cell therapy, ronde-cel, against other treatments for relapsed large B-cell lymphoma. This trial is notable for being the first head-to-head comparison of CAR T-cell therapies. The company aims to gather critical data to support treatment decisions and regulatory submissions.
Read more →LYEL▲ +12.3%on this news· ran to +32% by day 3
Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition
Lyell Immunopharma presented new clinical data for ronde-cel at the 67th ASH Annual Meeting, showing high rates of durable complete responses in patients with large B-cell lymphoma. The ongoing trial reported a 93% overall response rate and a 76% complete response rate in relapsed/refractory cases. Ronde-cel has received RMAT designation from the FDA, indicating its potential for outpatient treatment.
Read more →LYELLyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2025
Lyell Immunopharma reported its Q3 2025 financial results, highlighting advancements in its CAR T-cell therapy pipeline, including the promising ronde-cel for relapsed large B-cell lymphoma. The FDA granted RMAT designation for this therapy, and the company also acquired LYL273 for metastatic colorectal cancer. Despite a reduced net loss compared to last year, challenges remain in clinical trial execution and financial sustainability.
Read more →LYELLyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal Cancer
Lyell Immunopharma has acquired global rights to LYL273, a CAR T-cell therapy for metastatic colorectal cancer, from Innovative Cellular Therapeutics. The therapy demonstrated a 67% overall response rate in a Phase 1 trial. Despite promising results, there were notable treatment-related adverse events, including severe complications in one patient. The acquisition is expected to enhance Lyell's pipeline and address significant needs in cancer treatment.
Read more →LYELLyell Announces Two Oral Presentations from the Phase 1/2 Clinical Trial of Ronde-Cel for the Treatment of Aggressive Large B-Cell Lymphoma at the 67th ASH Annual Meeting and Exposition
Lyell Immunopharma announced two oral presentations at the 67th ASH Annual Meeting, showcasing new clinical data from the Phase 1/2 trial of ronde-cel for aggressive large B-cell lymphoma (LBCL). The dual-targeting CAR T-cell therapy has shown promising response rates and safety profiles. The FDA has granted it RMAT and Fast Track designations, indicating its potential in treating relapsed LBCL.
Read more →LYELLyell Immunopharma Announces the Initiation of a Phase 3 Head-to-Head CAR T-Cell Therapy Clinical Trial in Aggressive Large B-Cell Lymphoma and Formation of Expert Steering Committee
Lyell Immunopharma has launched the PiNACLE - H2H Phase 3 clinical trial, comparing its dual-targeting CAR T-cell therapy, ronde-cel, against existing therapies for relapsed or refractory large B-cell lymphoma. The trial aims to demonstrate the potential clinical benefits of ronde-cel, which has received RMAT and Fast Track designations from the FDA. Enrollment is expected to start by early 2026.
Read more →LYELLyell Immunopharma Announces Participation in September Investor Conferences
Lyell Immunopharma announced its participation in upcoming investor conferences, where senior management will present updates on the company's advancements in CAR T-cell therapies. The company focuses on innovative treatments for cancer, particularly through its lead candidate, LYL314, which aims to enhance treatment outcomes for large B-cell lymphoma patients. A live webcast of the presentations will be available on their website.
Read more →LYELLyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2025 Presented positive new clinical data demonstrating high rates of durable complete responses from the Phase 1 2 trial of LYL
Lyell Immunopharma has reported promising clinical data for its lead product candidate, LYL314, showing high rates of durable complete responses in patients with aggressive large B-cell lymphoma. The company has initiated the PiNACLE pivotal trial in patients receiving treatment in later lines and plans to begin a second pivotal trial for second-line treatment by early 2026. Additionally, a private placement has secured up to $100 million to support further development, with enough cash expected to last into mid-2027.
Read more →LYEL▲ +19.3%on this news· ran to +32% by day 1
Lyell Immunopharma Announces up to $100 Million Equity Private Placement
Lyell Immunopharma has announced a private placement agreement to raise up to $100 million, with an initial closing of $50 million expected soon. The funds will support pivotal trials for its CAR T-cell therapy, LYL314, aimed at treating large B-cell lymphoma. The company anticipates sufficient capital to sustain operations through mid-2027, including the submission of a Biologics License Application in 2027.
Read more →LYEL▲ +6.6%on this news
Lyell Immunopharma to Participate in the H.C. Wainwright “HCW@Home” Series
Lyell Immunopharma will participate in the H.C. Wainwright 'HCW@Home' Series on June 25, 2025, showcasing new clinical data for its lead candidate LYL314. This dual-targeting CAR T-cell therapy is in pivotal development for relapsed/refractory large B-cell lymphoma and has received FDA designations. The event will be accessible via a live webcast.
Read more →LYELLyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell Lymphoma
Lyell Immunopharma has announced promising results from its Phase 1/2 trial of LYL314 for aggressive large B-cell lymphoma. The trial showed an 88% overall response rate and a 72% complete response rate in patients treated in the third-line or later setting. The company is advancing to a pivotal trial, PiNACLE, to further evaluate LYL314's efficacy.
Read more →LYEL▼ -13.4%on this news· ran to -25% by day 1
Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments
Lyell Immunopharma has announced key appointments to enhance its clinical and commercial capabilities. Mark J. Bachleda joins as an independent board member, David Shook as Chief Medical Officer, and Mark Meltz as General Counsel. These additions are expected to support the advancement of LYL314, a CAR T-cell therapy for aggressive large B-cell lymphoma, towards approval.
Read more →LYEL▲ +68.6%on this newsshared move
Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference
Lyell Immunopharma, a clinical-stage company specializing in CAR T-cell therapies, is set to present at the Goldman Sachs Global Healthcare Conference on June 11th. This participation highlights the company's commitment to advancing its therapeutic pipeline aimed at treating various types of cancer. A live webcast of the presentation will be available on their website, ensuring broader access to interested parties. Lyell's innovative approach may attract attention from investors and stakeholders in the biopharma sector.
Read more →LYELLyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025 Presenting new clinical data from Phase 1 2 multi-center clinical trial of LYL314, a next-generation dual targeting CD19 CD2
Lyell Immunopharma has reported significant business highlights and financial results for Q1 2025, focusing on its lead product candidate, LYL314, a dual-targeting CAR T-cell therapy for large B-cell lymphoma. The company received FDA's RMAT designation, allowing for expedited development processes. Promising clinical data revealing a 94% overall response rate in preliminary trials will be presented at an upcoming international lymphoma conference. With manufacturing capabilities established at its facility, Lyell plans to initiate pivotal trials in both third- and second-line settings by mid-2025 and early 2026, respectively.
Read more →LYELLyell Immunopharma Announces Oral Presentation of New Clinical Data from the Phase 1/2 Trial of LYL314 for the Treatment of Large B-cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) 2025
Lyell Immunopharma announced that new clinical data from the Phase 1/2 trial of LYL314 for large B-cell lymphoma will be presented at the ICML 2025 conference. The product candidate, a dual-targeting CD19/CD20 CAR T-cell therapy, has shown high rates of durable complete responses in patients. Additionally, LYL314 has been granted regulatory designations from the FDA, highlighting its potential in treating aggressive lymphoma. The presentation is scheduled for June 18, 2025, in Lugano, Switzerland.
Read more →LYELLyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma
Lyell Immunopharma has been granted Regenerative Medicine Advanced Therapy (RMAT) designation for its CAR T-cell therapy LYL314, targeting relapsed and/or refractory large B-cell lymphoma. This designation underscores the therapy's potential to fulfill unmet medical needs and facilitates enhanced communication with the FDA. Initial clinical data reveal a 94% overall response rate among patients in trials, providing optimism for its effectiveness in treating this aggressive cancer. Future clinical data presentations are anticipated throughout 2025, showcasing further developments in LYL314’s clinical trial progress.
Read more →LYELLyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2024 Acquired ImmPACT Bio and strengthened clinical pipeline with the addition of IMPT-314, a next-generation dual
Lyell Immunopharma reported its fourth-quarter and full-year financial results for 2024, highlighting a transformative year with the acquisition of ImmPACT Bio and advancements in its clinical pipeline. The company showcased positive initial data from a Phase 1 trial of IMPT-314, a next-generation CAR T-cell therapy for aggressive large B-cell lymphoma. With expectations to initiate pivotal trials in mid-2025 and early 2026, Lyell aims to enhance patient outcomes. Despite a substantial net loss, its strong cash position supports ongoing development through 2027.
Read more →LYELLyell Immunopharma Announces Participation in Upcoming Investor Conferences
Lyell Immunopharma, a clinical-stage company specializing in CAR T-cell therapies, has announced its participation in two upcoming investor conferences. These events are the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference on February 25th and TD Cowen's 45th Annual Health Care Conference on March 3rd. This participation highlights the company's ongoing efforts to advance its innovative cancer treatments and engage with investors regarding their pipeline. More details can be accessed through the company's investor relations section on their website.
Read more →LYEL▼ -7.3%on this news
Lyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare Conference
Lyell Immunopharma is set to showcase its next-generation CAR T-cell therapy, IMPT-314, at the upcoming JP Morgan Healthcare Conference. The therapy aims to improve treatment outcomes for patients with aggressive large B-cell lymphoma, demonstrating an impressive 94% overall response rate in early trials. Although the company is halting development of another candidate, LYL119, it retains focus on IMPT-314 and plans pivotal trials in the coming years. With financial projections extending its cash runway into 2027, Lyell is positioned for potential growth as it accelerates its pipeline of innovative therapies.
Read more →LYELLyell Presents Positive Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 ASH Annual Meeting Objective response rate (ORR) of 94% and a complete response
Lyell Immunopharma has reported promising initial clinical data from the Phase 1-2 trial of IMPT-314 for treating large B-cell lymphoma at the 2024 ASH Annual Meeting. The treatment revealed a 94% objective response rate, with 71% of patients achieving a complete response within three months. The safety profile appears positive, with no severe cases of cytokine release syndrome. The company aims to initiate a pivotal trial for IMPT-314 in 2025, following this encouraging data presentation.
Read more →LYEL▼ -17.6%on this news
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2024 Acquired ImmPACT Bio and strengthened clinical pipeline with the addition of IMPT-314, a dual-targeting CD19 CD20 CAR T-cell
Lyell Immunopharma reported business highlights and financial results for Q3 2024, detailing the acquisition of ImmPACT Bio and advancements in its clinical pipeline, notably the dual-targeting CAR T-cell product candidate IMPT-314. Initial Phase 1 data for IMPT-314 will be presented at the ASH Annual Meeting, with plans for a pivotal trial in 2025. Despite a net loss of $44.6 million, Lyell's strong cash reserves of $460.7 million are projected to fund operations through 2027, supporting further development of its innovative therapies in hematologic malignancies.
Read more →LYELLyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting
Lyell Immunopharma announced the presentation of initial clinical data for its IMPT-314 product candidate at the upcoming 2024 ASH Annual Meeting. The dual-targeting CAR T-cell therapy targets aggressive B-cell lymphoma and has been granted Fast Track Designation by the FDA. The data will be presented by Dr. Sarah M. Larson at the conference, which is taking place in San Diego. Despite positive developments, the company faces various risks and uncertainties related to its clinical trials and regulatory approvals.
Read more →LYEL▲ +11.9%on this news· ran to +44% by day 3shared move
Lyell Immunopharma Completes Acquisition of ImmPACT Bio Acquisition strengthens Lyell s clinical pipeline with the addition of IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate expected to initiate pivota
Lyell Immunopharma has completed its acquisition of ImmPACT Bio, enhancing its CAR T-cell therapy pipeline. The addition of IMPT-314, targeting hematologic malignancies, is expected to accelerate treatment development. Former ImmPACT CEO Dr. Sumant Ramachandra joins Lyell's Board of Directors to guide the integration of the two companies. Lyell anticipates that its cash reserves will support operations into 2027 through significant clinical milestones, including a pivotal trial for IMPT-314 starting in 2025.
Read more →LYEL▼ -5.2%on this news· ran to -19% by day 1
Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies Strengthens Lyell s clinical pipeline with the addition of IMPT-314, a dual-targeting CD19/CD20 CAR
Lyell Immunopharma has announced a definitive agreement to acquire ImmPACT Bio, enhancing its clinical pipeline with the addition of the dual-targeting CAR T-cell therapy IMPT-314 for hematologic malignancies. The acquisition aims to position Lyell for stronger outcomes in CAR T-cell therapies, improving on existing treatments for aggressive B-cell lymphoma. Notably, IMPT-314 has exhibited promising clinical response rates in trials. However, Lyell will discontinue its ongoing projects on LYL797 and LYL845 to streamline its pipeline initiatives. The transaction awaits customary closing conditions, with an expected close in Q4 2024.
Read more →LYELLyell Immunopharma Announces the Acceptance Abstracts for Presentation at 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Lyell Immunopharma announced the acceptance of three abstracts for presentation at the 2024 Society for Immunotherapy of Cancer Annual Meeting. These presentations will showcase data on their innovative anti-exhaustion technology and product candidates aimed at treating solid tumors and hematologic malignancies. Notably, the LYL797 Phase 1 clinical trial data will be presented for the first time, highlighting tumor infiltration and cytotoxic activity. The conference is set to take place in Houston, TX, from November 6-10, 2024.
Read more →LYELLyell Immunopharma Announces Participation in Goldman Sachs Cell Therapy Day
Lyell Immunopharma, a clinical-stage T-cell reprogramming company, has announced that its President & CEO, Lynn Seely, will participate in a panel discussion on next-generation cell therapies at Goldman Sachs Cell Therapy Day on October 1. The company is progressing a pipeline of cell therapies aimed at treating solid tumors and hematologic malignancies, with several product candidates entering Phase 1 clinical development. Lyell employs novel anti-exhaustion technology aimed at enhancing the effectiveness and durability of its therapies.
Read more →LYELLyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2024 Reported dose-dependent antitumor clinical activity in patients with relapsed refractory triple-negative breast cancer from
Lyell Immunopharma has reported encouraging results from its second quarter 2024, highlighting dose-dependent antitumor activity in patients with relapsed refractory triple-negative breast cancer from its LYL797 trial. The company has also expanded the trial to include patients with several additional cancer types and received FDA clearance for its next-generation CAR T-cell product, LYL119. Despite a net loss reported, the company maintains a robust cash position to advance its diverse pipeline through 2027, with expectations of new clinical data and trials forthcoming.
Read more →LYEL▼ -36%on this news
Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion Technology Dose-dependent antitumor cli
Lyell Immunopharma reported promising initial results from its Phase 1 trial of LYL797, a CAR-T therapy targeting ROR1 in patients with triple-negative breast cancer (TNBC). The treatment showed a 40% objective response rate and a 60% clinical benefit rate at the highest dose level tested. While there were treatment-related adverse events, including pneumonitis and cytokine release syndrome, no dose-limiting toxicities occurred in patients without lung involvement. The company is encouraged by these results and plans to expand the trial to include additional cancer types.
Read more →LYELLyell Immunopharma to Participate in BofA Securities Health Care Conference
Lyell Immunopharma, a clinical-stage T-cell reprogramming firm, announced its participation in the BofA Securities 2024 Health Care Conference on May 14 at 8:40 am PT. The event presents an opportunity for the company's management to discuss their pipeline of cell therapies aimed at treating solid tumors such as triple-negative breast cancer and non-small cell lung cancer. The presentation will be accessible via a live webcast, with a replay available afterward on the company's website. Lyell's innovative approaches in tackling challenges related to T-cell therapy are central to their mission.
Read more →LYEL▲ +7.6%on this newsshared move
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024 Expect to share initial clinical and translational data from the Phase 1 trial of LYL797, a ROR1-targeted CAR T cell product
Lyell Immunopharma reported its first quarter 2024 business highlights and financial results, emphasizing the anticipated initial clinical data from its lead product candidate, LYL797, in the ongoing Phase 1 trial. The company is actively engaged in advancing four product candidates, including LYL845, with updates expected later this fiscal year. Financially, Lyell maintains a robust cash position, projected to support operations through multiple clinical milestones up until 2027. The company continues to focus on innovative therapies for patients with solid tumors.
Read more →LYELLyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting
Lyell Immunopharma has announced the acceptance of three abstracts for presentation at the upcoming AACR Annual Meeting 2024. The presentations will showcase advancements in their product pipeline, including rejuvenation technology aimed at improving T cell function and a second-generation ROR1-targeted CAR T-cell therapy, LYL119. These developments signify progress in Lyell's efforts to tackle solid tumors with innovative cell therapies. The meeting is scheduled to take place in San Diego from April 5 to 10, 2024.
Read more →LYELLyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023 On track to report initial clinical and translational data from lead CAR T-cell and TIL product candidates in
Lyell Immunopharma has announced its business highlights and financial results for the fourth quarter and full year of 2023. The company is on track to report initial clinical data from its CAR T-cell and TIL candidates in 2024, with strong progress in its development pipeline. Notably, Lyell received Orphan Drug Designation for LYL845, intended for melanoma treatment, and it maintained a robust cash reserve to support future clinical milestones. However, the firm also reported considerable financial losses and a drop in revenue due to the cessation of a previous collaboration.
Read more →LYEL▼ -5.7%on this news
Lyell Immunopharma to Participate in 42nd Annual J.P. Morgan Healthcare Conference
Lyell Immunopharma, a clinical-stage T-cell reprogramming company, announced its participation in the 42nd Annual J.P. Morgan Healthcare Conference scheduled for January 10, 2024. The company's management will present details about their pipeline of cell therapies targeting solid tumors, including ongoing Phase 1 clinical trials. Lyell's innovative approaches focus on addressing challenges in cell therapy, such as T-cell exhaustion and durability of response. The event will feature both a live presentation and a subsequent webcast available on their website.
Read more →LYEL▼ -6.8%on this news· ran to -30% by day 1
Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of Melanoma
Lyell Immunopharma announced that the FDA has granted Orphan Drug Designation for its investigational product LYL845, intended for the treatment of stage IIB-IV melanoma. This designation is significant, as it provides certain incentives for drug development aimed at diseases affecting fewer than 200,000 patients in the U.S. LYL845, which is being evaluated in a Phase 1 clinical trial, aims to improve treatment outcomes through its enhanced T-cell technology. Initial clinical data is anticipated in 2024, with the potential for LYL845 to address unmet medical needs in melanoma and other solid tumors.
Read more →LYELLyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023 Extended funding of operations into 2027 by prioritizing investment in core clinical candidates and research platform value
Lyell Immunopharma reported its financial results and business highlights for Q3 2023, extending its operational funding through 2027 by prioritizing investments in core clinical candidates. The company is on track to present initial clinical data from two lead programs in 2024, while also entering a manufacturing collaboration with Cellares aimed at improving CAR T-cell therapy efficiency. However, the restructuring will result in a 25% workforce reduction and a net loss of $50.9 million. Despite these challenges, the pipeline's clinical development continues to show promise with key trials and advancements underway.
Read more →LYEL▼ -7.5%on this news· ran to +20% by day 3
Lyell Immunopharma Presentations at SITC Highlight New Nonclinical Data on Product Candidates and Innovative Technology to Shorten TIL Manufacturing
Lyell Immunopharma is presenting new nonclinical data at the SITC Annual Meeting, showcasing advancements in TIL manufacturing and details on LYL119, a ROR1-targeted CAR T-cell approach. The newly introduced Epi-R P2 manufacturing protocol significantly reduces TIL production time without compromising quality. Additionally, LYL119 has demonstrated enhanced efficacy in preclinical models, along with innovative technologies aimed at improving solid tumor therapies. The company is also detailing its ongoing Phase 1 clinical trials for LYL797 and LYL845 in various solid tumor types.
Read more →LYELLyell Immunopharma Announces the Acceptance of Six Abstracts for Presentation at 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Lyell Immunopharma announced the acceptance of six abstracts for presentation at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting. The abstracts cover various aspects of their T-cell reprogramming technologies, including new nonclinical data and ongoing Phase 1 clinical trials for therapies targeting solid tumors. The presentations will emphasize advancements such as the Epi-R P2 manufacturing process and collaborations aimed at enhancing solid tumor T-cell therapies. The SITC meeting will take place in San Diego from November 1 to 5, 2023.
Read more →LYEL▲ +9.9%on this news
DRAFT JPM22 Updated 12-14-21 Lyell Immunopharma
Lyell Immunopharma has outlined its forward-looking strategy and goals for advancing its innovative cell therapies targeting solid tumors. The company is set to report clinical data from two promising programs in 2024, including a notable CAR T cell therapy, LYL797, designed for relapsed/refractory cancers. With a robust financial position, Lyell aims to address significant unmet medical needs in cancer treatment. However, the company faces various risks and challenges related to clinical trials and regulatory approvals.
Read more →LYELLyell Immunopharma to Participate in Upcoming Investor Conferences
Lyell Immunopharma, a clinical-stage T-cell reprogramming company, will participate in several upcoming healthcare conferences, providing updates on its cell therapy initiatives. The events include the Morgan Stanley 21st Annual Global Healthcare Conference and the H.C. Wainwright 25th Annual Global Investment Conference. These engagements signal the company's effort to keep investors informed about its diverse pipeline aimed at treating solid tumors, such as triple-negative breast cancer and non-small cell lung cancer. Live webcasts of the presentations will be available on their website, reinforcing transparency and investor relations.
Read more →LYELLyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2023 Cash, cash equivalents and marketable securities of $632.7 million as of
Lyell Immunopharma has announced its business highlights and financial results for the second quarter of 2023. The company reported a net loss of $63.9 million, while maintaining $632.7 million in cash to support ongoing clinical trials. Initial clinical data from two of its lead product candidates, LYL797 and LYL845, is anticipated in 2024. Additionally, the appointment of new Chief Business Officer Matt Lang aims to strengthen its executive leadership amid ongoing developments in its diverse pipeline of cell therapies for solid tumors.
Read more →LYELLyell Immunopharma Appoints Matthew Lang as Chief Business Officer
Lyell Immunopharma has appointed Matthew Lang as its Chief Business Officer, a newly created position. Lang will oversee legal, compliance, human resources, and commercialization efforts while playing a key role on the executive committee. His extensive experience in the biopharma industry, including significant roles at Myovant Sciences and Gilead Sciences, positions him well to help advance Lyell's mission of developing innovative cell therapies for solid tumors. The company anticipates initial clinical data for its product candidates next year.
Read more →LYELLyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2023 Two phase 1 clinical trials recruiting patients at 14 sites across the US nine sites for LYL797, a ROR-1-targeted chimeric a
Lyell Immunopharma reported its business activities and financial results for the first quarter of 2023, highlighting two active Phase 1 clinical trials for its CAR-T and TIL product candidates, LYL797 and LYL845, respectively. The company has a solid financial position with $668 million available to support its development pipeline through 2026. However, it also reported a net loss of $67 million in the first quarter, and its revenue decreased significantly after ending its collaboration with GlaxoSmithKline. Initial clinical data is expected in 2024, with the company focused on advancing innovative therapies for patients with solid tumors.
Read more →LYELLyell Immunopharma to Participate in BofA Securities Healthcare Conference
Lyell Immunopharma, Inc. announced that its senior management will participate in the BofA Securities 2023 Healthcare Conference on May 9 at 3:00 pm PT. A live webcast of the event will be accessible through the company's investor relations website, with a replay available for 90 days post-event. Lyell is focused on developing innovative cell therapies specifically targeting solid tumors, utilizing proprietary technologies to improve clinical outcomes.
Read more →LYELLyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2022 Cash, cash equivalents and marketable securities of $710.3 million as of
Lyell Immunopharma has reported its business highlights and financial results for the fourth quarter and full year of 2022. The company has initiated two Phase 1 clinical trials for solid tumor treatments, backed by a strong cash position of $710.3 million. Despite a reported net loss of $183.1 million for 2022, the company anticipates further momentum in their clinical programs and has presented encouraging data related to their advanced therapies at scientific events. They continue to invest in innovative technologies to enhance the effectiveness of their T-cell therapies.
Read more →LYELLyell Immunopharma to Participate in 41st Annual J.P. Morgan Healthcare Conference
Lyell Immunopharma, a clinical-stage company focused on T-cell reprogramming, has announced participation in the upcoming 41st Annual J.P. Morgan Healthcare Conference. At the event, the company's management team will present its growing pipeline targeting solid tumors and innovations in T-cell technologies, including several product candidates in clinical development. Key highlights include advancements in CAR T cell therapies and novel reprogramming technologies aimed at improving therapeutic efficacy. The participation underscores Lyell's commitment to showcasing its strategies and innovations in the competitive biopharma landscape.
Read more →LYEL▼ -7.9%on this news
Lyell Immunopharma Appoints Lynn Seely, MD as President and Chief Executive Officer
Lyell Immunopharma Appoints Lynn Seely, MD as President and Chief Executive Officer SOUTH SAN FRANCISCO, Calif., Dec. 15, 2022 Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage T-cell reprogramming company dedicated to developing curative cell therapies for patients wit
Read more →LYELLyell Immunopharma to Participate in BofA Securities Biotech Conference
SOUTH SAN FRANCISCO, Calif., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, today announced that members of its senior managem
Read more →LYEL▲ +11.2%on this news
Lyell Immunopharma to Participate in Barclays Virtual Fireside Chat Series
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, announced today that members of its senior managem
Read more →LYELLyell Immunopharma Reports Recent Business Highlights and Third Quarter Financial Results Investigational New Drug (IND) application clearance of LYL845 advances second wholly owned product candidate into clinical develo
Lyell Immunopharma Reports Recent Business Highlights and Third Quarter Financial Results Investigational New Drug (IND) application clearance of LYL845 advances second wholly owned product candidate into clinical development Cash, cash equivalents and marketable securities of
Read more →LYELLyell Immunopharma Presents New Data at SITC Highlighting its Growing Pipeline of T – Cell Reprogramming Technologies and Product Candidates Targeting Solid Tumors
Preclinical data demonstrate genetic and epigenetic reprogramming can ameliorate T cell exhaustion and enhance stem-like qualities and potency of T cells in various modalities SOUTH SAN FRANCISCO, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL),
Read more →LYEL▼ -6%on this newsshared move
Lyell Immunopharma to Participate in Credit Suisse Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, announced today that members of its senior managem
Read more →LYELLyell Immunopharma Announces FDA Clearance of its IND for LYL845, a TIL Product Candidate Enhanced with its Novel Epigenetic Reprogramming Technology for Solid Tumors Autologous TIL therapy enhanced with Lyell s Epi-R re
Lyell Immunopharma Announces FDA Clearance of its IND for LYL845, a TIL Product Candidate Enhanced with its Novel Epigenetic Reprogramming Technology for Solid Tumors SOUTH SAN FRANCISCO, Calif., Oct 6, 2022 Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage T-cell repr
Read more →LYELLyell Immunopharma to Present Preclinical Data Highlighting New T-Cell Reprogramming Technologies and its Growing Pipeline at 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Five poster presentations to include preclinical data describing new T-cell reprogramming technology being incorporated in LYL119, Lyell’s next product candidate SOUTH SAN FRANCISCO, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-st
Read more →LYEL▲ +13%on this news
Lyell Immunopharma Announces the Appointment of Rahsaan Thompson as Chief Legal Officer
SOUTH SAN FRANCISCO, Calif., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, announced that Rahsaan W. Thompson has joined the
Read more →LYEL▲ +9%on this news
Lyell Immunopharma Presents First in Human Trial Design of LYL797 at ESMO 2022
SOUTH SAN FRANCISCO, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, announced today that a poster describing the firs
Read more →LYELLyell Immunopharma to Participate in Morgan Stanley Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, announced today that members of its senior managem
Read more →LYEL▲ +6.4%on this news· ran to +20% by day 3
Lyell Immunopharma Reports Second Quarter Financial Results and Business Highlights Cash, cash equivalents and marketable securities of $787.0 million as of
Lyell Immunopharma Reports Second Quarter Financial Results and Business Highlights Cash, cash equivalents and marketable securities of $787.0 million as of June 30, 2022 provides funding into 2025 and supports advancement of multiple product candidates through key clinical mile
Read more →LYEL▲ +6.9%on this news
Lyell Immunopharma to Participate in Goldman Sachs Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc., (Nasdaq: LYEL), a clinical-stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, today announced that members of its senior manage
Read more →LYELLyell Immunopharma Reports First Quarter Financial Results and Business Highlights Cash, cash equivalents and marketable securities of $838 million as of
Lyell Immunopharma Reports First Quarter Financial Results and Business Highlights Cash, cash equivalents and marketable securities of $838 million as of March 31, 2022 supports advancing a robust cell therapy pipeline Research highlighting novel reprogramming technologies desi
Read more →LYEL▲ +6%on this newsshared move
Lyell Immunopharma to Present Preclinical Data for Two Product Candidates in Clinical Development at ASGCT Annual Meeting
SOUTH SAN FRANCISCO, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc., (Nasdaq: LYEL), a T-cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors, announced today that two abstracts have been accepted for poster presenta
Read more →LYELLyell Immunopharma Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights Cash, cash equivalents and marketable securities of $898 million as of
Lyell Immunopharma Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights Cash, cash equivalents and marketable securities of $898 million as of December 31, 2021 supports advancing multi-modality cell therapy pipeline Clinical development commencin
Read more →LYEL▼ -5.2%on this news
Lyell Immunopharma Announces Upcoming Presentation on LYL797 at the American Association for Cancer Research (AACR) 2022 Annual Meeting
LYL797 is an investigational ROR1 CAR T-cell therapy incorporating novel reprogramming technologies for solid tumors SOUTH SAN FRANCISCO, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Lyell), (Nasdaq: LYEL), a T-cell reprogramming company dedicated to the
Read more →LYEL▲ +8.2%on this news
Lyell Immunopharma Appoints Gary Lee, Ph.D. as Chief Scientific Officer
SOUTH SAN FRANCISCO, Calif., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc., (Nasdaq: LYEL), a T-cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors, today announced the appointment of Gary Lee, Ph.D., as Chief Scientific
Read more →LYELLyell Immunopharma Announces FDA Clearance of IND for LYL132, a T-Cell Receptor Therapy for Solid Tumors Being Developed in Collaboration with GSK
SOUTH SAN FRANCISCO, Calif., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc., (Nasdaq: LYEL), a T-cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors, announced today that the U.S. Food and Drug Administration (FDA) has cle
Read more →LYEL▼ -8.4%on this news
Lyell Immunopharma to Participate in 40th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc., (NASDAQ: LYEL), a T-cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors, today announced that members of its senior management team will particip
Read more →LYELLyell Immunopharma Announces FDA Clearance of its IND for LYL797, a CAR T-Cell Therapy Incorporating Novel Reprogramming Technologies for Solid Tumors
Expects to begin screening patients for the Phase 1 clinical trial by the end of the first quarter; initial data presentation expected in 2023 ROR1-targeted CAR T-cell therapy designed to overcome T-cell exhaustion and promote durable stemness incorporates Lyell’s novel genetic
Read more →LYEL▼ -7.6%on this news· ran to -23% by day 3shared move
Lyell Immunopharma Announces cGMP Qualification of LyFE Manufacturing Center in Advance of Initiating Clinical Programs Lyell s cGMP-compliant manufacturing facility, is designed to produce cell products at scale for upc
Lyell Immunopharma Announces cGMP Qualification of LyFE Manufacturing Center in Advance of Initiating Clinical Programs SOUTH SAN FRANCISCO, Calif., Dec. 15, 2021 Lyell Immunopharma, Inc. (Lyell), (Nasdaq: LYEL), a T-cell reprogramming company dedicated to the mastery of T cel
Read more →LYELLyell Immunopharma Announces Return of Dr. Rick Klausner as Board Chair
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Lyell), (Nasdaq: LYEL), a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors, today announced that Dr. Rick Klausner is resuming his role as C
Read more →LYELLyell Immunopharma Reports Third Quarter 2021 Financial Results and Business Highlights ● Cash and investments of $936.4 million as of
Lyell Immunopharma Reports Third Quarter 2021 Financial Results and Business Highlights Cash and investments of $936.4 million as of September 30, 2021 supports advancing multi-modality cell therapy pipeline SOUTH SAN FRANCISCO, Calif., Nov 12, 2021 -- Lyell Immunopharma, Inc.
Read more →LYELDear Colleagues and Stockholders: I am writing to let you know that I am taking a temporary medical leave of absence from Lyell as a result of a recent health situation. I expect to make a full recovery and to return in
Dear Colleagues and Stockholders: I am writing to let you know that I am taking a temporary medical leave of absence from Lyell as a result of a recent health situation. I expect to make a full recovery and to return in early 2022. I want to personally thank all Lyellites for
Read more →LYELLyell Immunopharma Reports Second Quarter 2021 Financial Results and Business Highlights ● Achieved operational readiness of state-of-the-art LyFE manufacturing facility to support multiple clinical trials ●
Lyell Immunopharma Reports Second Quarter 2021 Financial Results and Business Highlights Achieved operational readiness of state-of-the-art LyFE manufacturing facility to support multiple clinical trials Cash, cash equivalents and marketable securities of $974.8 million as of J
Read more →LYELLyell Immunopharma Announces Pricing of Initial Public Offering
SOUTH SAN FRANCISCO, Calif., June 16, 2021 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Lyell), (Nasdaq: LYEL), a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors, today announced the pricing of its initial public offering of 25
Read more →Competitive Position
How LYEL ranks across every disease it competes inCompetitive Position is a premium feature
See how LYEL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial